Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 4, 2022Molecular CancerOpen Access

Targeting KRAS mutant cancers: from druggable therapy to drug resistance

View Full Paper
Ask AI
Bookmark
Share

Authors

CZChunxiao ZhuWeifang Medical UniversityXGXiaoqing GuanShanghai University of Traditional Chinese MedicineXZXinuo ZhangBeijing Chao-Yang Hospital

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Zhu et al. (2022) studied this question.

synapsesocial.com/papers/69e783f1b1f585b14520bf46https://doi.org/10.1186/s12943-022-01629-2
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Isoform-Specific Destabilization of the Active Site Reveals a Molecular Mechanism of Intrinsic Activation of KRas G13D2019 · 89 citations
  2. 2First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study2017 · 425 citations
  3. 3Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor2004 · 1,705 citations